Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
26-week comparison of twice-daily insulin degludec/insulin aspart versus once-daily insulin degludec plus mealtime insulin aspart in adults with type 2 diabetes mellitus needing intensification
2012-002346-20Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2012
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin degludec + insulin aspart, insulin degludec and insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline in glycosylated haemoglobin. Started Oct 2012; status: completed.
02
Drugs
insulin degludec + insulin aspartinsulin degludecinsulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-002346-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002346-20.